Lonza Group Ag Change in Accounts Payable 2012-2024 | LZAGY
Lonza Group Ag annual/quarterly change in accounts payable history and growth rate from 2012 to 2024. Change in accounts payable can be defined as the increase or decrease in trade payables for the given period.
- Lonza Group Ag change in accounts payable for the quarter ending December 31, 2024 was $0M, a 0% increase year-over-year.
- Lonza Group Ag change in accounts payable for the twelve months ending December 31, 2024 was $0M, a 0% increase year-over-year.
- Lonza Group Ag annual change in accounts payable for 2023 was $-0.007B, a 218.85% increase from 2022.
- Lonza Group Ag annual change in accounts payable for 2022 was $-0.002B, a 100.9% decline from 2021.
- Lonza Group Ag annual change in accounts payable for 2021 was $0.233B, a 674.97% decline from 2020.
| Lonza Group Ag Annual Change in Accounts Payable (Millions of US $) |
|
|---|---|
| 2023 | $-7 |
| 2022 | $-2 |
| 2021 | $233 |
| 2020 | $-41 |
| 2019 | $40 |
| 2017 | $36 |
| 2016 | $-15 |
| 2015 | $N/A |
| 2014 | $N/A |
| 2013 | $N/A |
| 2012 | $N/A |
| 2011 | $N/A |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $49.624B | $7.468B |
| Lonza Group AG operates as a supplier to the pharmaceutical, healthcare and life-science industries. The Company divides its activities into four divisions: Life Science Ingredients; Microbial Control; Custom Manufacturing, and Bioscience. The company's Life Science Ingredients segment produces nutrition ingredients for applications in nutrition (food, feed and pharmaceutical application) and chemical intermediates for the agricultural industry. The Microbial Control division focuses on five areas: hygiene, wood protection, water treatment, oil/gas applications, and industrial preservation and comprises products ranging from disinfectants to household cleaning products. The Custom Manufacturing division comprises products used in pharmaceuticals sector. The Bioscience division comprises bioscience products, including cell culture and molecular biology tools for research, tests for microbial detection, and media used in the production of therapeutics. Lonza Group AG is headquartered in Basel, Switzerland. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $229.711B | 27.62 |
| Boston Scientific (BSX) | United States | $154.351B | 38.64 |
| Stryker (SYK) | United States | $149.416B | 31.24 |
| EssilorLuxottica (ESLOY) | France | $132.057B | 0.00 |
| Medtronic (MDT) | Ireland | $115.083B | 16.32 |
| Haleon (HLN) | United Kingdom | $44.474B | 25.39 |
| ResMed (RMD) | United States | $37.259B | 27.99 |
| Agilent Technologies (A) | United States | $34.110B | 22.24 |
| GE HealthCare Technologies (GEHC) | United States | $34.090B | 16.18 |
| Terumo (TRUMY) | Japan | $24.459B | 31.77 |
| Koninklijke Philips (PHG) | Netherlands | $23.149B | 16.24 |
| Insulet (PODD) | United States | $20.550B | 80.67 |
| Zimmer Biomet Holdings (ZBH) | United States | $18.570B | 11.93 |
| Baxter (BAX) | United States | $14.641B | 10.93 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $13.157B | 0.00 |
| Demant (WILYY) | Denmark | $8.633B | 0.00 |
| Sunny Optical Technology (SNPTF) | China | $8.561B | 0.00 |
| Bio-Rad Laboratories (BIO) | United States | $6.825B | 23.75 |
| Lantheus Holdings (LNTH) | United States | $5.747B | 14.50 |
| Prestige Consumer Healthcare (PBH) | United States | $3.776B | 16.87 |
| Perrigo (PRGO) | Ireland | $3.768B | 9.55 |
| Haemonetics (HAE) | United States | $3.683B | 16.77 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $3.459B | 0.00 |
| Envista Holdings (NVST) | United States | $3.395B | 28.21 |
| ICU Medical (ICUI) | United States | $3.220B | 23.75 |
| QuidelOrtho (QDEL) | United States | $1.952B | 13.42 |
| LeMaitre Vascular (LMAT) | United States | $1.900B | 42.47 |
| AtriCure (ATRC) | United States | $1.550B | 0.00 |
| Acuren (TIC) | United States | $1.455B | 0.00 |
| Green Thumb Industries (GTBIF) | United States | $1.374B | 30.91 |
| Phibro Animal Health (PAHC) | United States | $1.278B | 16.34 |
| AdaptHealth (AHCO) | United States | $1.237B | 12.56 |
| Neogen (NEOG) | United States | $1.133B | 14.50 |
| BioLife Solutions (BLFS) | United States | $1.053B | 0.00 |
| InMode (INMD) | Israel | $0.932B | 9.39 |
| Kestra Medical Technologies (KMTS) | United States | $0.792B | 0.00 |
| Curaleaf Holdings (CURLF) | Canada | $0.749B | 0.00 |
| Maravai LifeSciences Holdings (MRVI) | United States | $0.680B | 0.00 |
| Tilray Brands (TLRY) | Canada | $0.661B | 0.00 |
| Owens & Minor (OMI) | United States | $0.616B | 5.11 |
| Evolus (EOLS) | United States | $0.613B | 0.00 |
| CeriBell (CBLL) | United States | $0.592B | 0.00 |
| Valneva SE (VALN) | France | $0.517B | 0.00 |
| Surmodics (SRDX) | United States | $0.449B | 0.00 |
| SNDL (SNDL) | Canada | $0.415B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $0.337B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.327B | 12.02 |
| Sanuwave Health (SNWV) | United States | $0.310B | 0.00 |
| Cresco Labs (CRLBF) | United States | $0.306B | 0.00 |
| SEMPERIT AG HLD (SEIGY) | Austria | $0.304B | 0.00 |
| Quanterix (QTRX) | United States | $0.302B | 0.00 |
| Cerus (CERS) | United States | $0.277B | 0.00 |
| Viemed Healthcare (VMD) | United States | $0.266B | 22.40 |
| Aurora Cannabis (ACB) | Canada | $0.257B | 76.33 |
| Sanara MedTech (SMTI) | United States | $0.257B | 0.00 |
| ZimVie (ZIMV) | United States | $0.249B | 11.30 |
| Brainsway (BWAY) | Israel | $0.231B | 61.17 |
| Omeros (OMER) | United States | $0.230B | 0.00 |
| OraSure Technologies (OSUR) | United States | $0.230B | 0.00 |
| Verano Holdings (VRNOF) | United States | $0.226B | 0.00 |
| Biote (BTMD) | United States | $0.221B | 6.22 |
| Canopy Growth (CGC) | Canada | $0.215B | 0.00 |
| Organigram Global (OGI) | Canada | $0.198B | 0.00 |
| High Tide (HITI) | Canada | $0.195B | 0.00 |
| TriSalus Life Sciences (TLSI) | United States | $0.188B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.184B | 15.00 |
| Vireo Growth (VREOF) | United States | $0.162B | 0.00 |
| Exagen (XGN) | United States | $0.151B | 0.00 |
| FitLife Brands (FTLF) | United States | $0.123B | 15.13 |
| TerrAscend (TSNDF) | Canada | $0.115B | 0.00 |
| Fonar (FONR) | United States | $0.101B | 13.05 |
| MacroGenics (MGNX) | United States | $0.100B | 0.00 |
| Jin Medical (ZJYL) | China | $0.094B | 0.00 |
| Jushi Holdings (JUSHF) | United States | $0.092B | 0.00 |
| Veru (VERU) | United States | $0.089B | 0.00 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.087B | 0.00 |
| Quipt Home Medical (QIPT) | United States | $0.083B | 0.00 |
| Apyx Medical (APYX) | United States | $0.074B | 0.00 |
| InterCure (INCR) | Israel | $0.071B | 0.00 |
| Agape ATP (ATPC) | $0.069B | 0.00 | |
| Cytosorbents (CTSO) | United States | $0.066B | 0.00 |
| Zynex (ZYXI) | United States | $0.064B | 0.00 |
| ImmuCell (ICCC) | United States | $0.059B | 0.00 |
| Nephros (NEPH) | United States | $0.040B | 54.00 |
| Safety Shot (SHOT) | United States | $0.040B | 0.00 |
| Modular Medical (MODD) | United States | $0.039B | 0.00 |
| Rockwell Medical (RMTI) | United States | $0.038B | 0.00 |
| United-Guardian (UG) | United States | $0.037B | 12.87 |
| Allurion Technologies (ALUR) | United States | $0.021B | 0.00 |
| Flora Growth (FLGC) | United States | $0.016B | 0.00 |
| INLIF (INLF) | $0.015B | 0.00 | |
| Meihua Medical Technologies (MHUA) | China | $0.014B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.013B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.013B | 0.00 |
| Senestech (SNES) | United States | $0.011B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.009B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.007B | 0.00 |
| Sharps Technology (STSS) | United States | $0.006B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.003B | 0.00 |
| Akanda (AKAN) | Canada | $0.002B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.000B | 0.00 |